RecruitingNCT07193069
Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning
Sponsor
Centre Hospitalier de Saint-Denis
Enrollment
50 participants
Start Date
Apr 11, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Adults aged 18 years or older
- Admission to an intensive care unit (ICU) due to acute drug poisoning
- Documented exposure to either:
- Metformin alone
- Metformin in combination with dapagliflozin
Exclusion Criteria3
- Patients under 18 years of age
- No exposure to metformin
- Exposure to dapagliflozin without metformin
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07193069
Related Trials
Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes
NCT074838791 location
Social Network Overdose Prevention and Education Intervention
NCT063270611 location
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
NCT071676931 location
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT0291519840 locations
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
NCT055328131 location